Navigation Links
'First-in-human' drug for malignant glioma available in experimental trial
Date:2/15/2012

CINCINNATI -- The UC Cancer Institute is one of three centers internationally approved to test an experimental drug's safety and pharmacokinetics and also assess the clinical benefit against recurrent malignant glioma, an aggressive form of brain cancer.

The "first-in-human" phase-1 trial is expected to enroll up to 60 patients at clinical sites in the United States and Australia.

Led by Olivier Rixe, MD, PhD, this experimental drug trial uses antibody-drug conjugate (ADC) technology, a new drug delivery concept currently being investigated in the treatment of various cancers. ADC molecules consist of an antibody linked to a specific cytotoxic drug that is intended to target, bind and disperse only in malignant cells.

The experimental drug (called AMG 595) is intended to target a specific mutated cell receptor (EGFRvIII) which exists on the surface of tumor cells in up to 30 percent of patients with malignant gliomas. Preliminary studies in animals have shown that ADC molecules can effectively find these specific cancer cells, then enter them and release an active cytotoxic agent with the aim of killing the tumor cells while minimizing damage to the surrounding normal tissue.

"This allows us to use a highly cytotoxic drug targeted to the cancer cells in the brain based on a specific cellular marker," explains Rixe, John and Gladys Strauss Chair in Cancer Research at the UC College of Medicine and director of the Experimental Therapeutics/Phase 1 Clinical Trials Program. "Until recently, primary brain tumor patients have traditionally been excluded from phase-1 oncology studies, so finding drugs to effectively target and make real advances against this particular type of very aggressive cancer has been virtually impossible."

Patients who have failed first- and second-line therapies for malignant glioma may qualify to participate in this trial. Potential candidates will be screened for the EGFRvIII mutation using tumor samples obtained during their original surgery prior to enrollment.

Each patient's response to the treatment and overall health will be clinically monitored through blood, urine and imaging tests at regular intervals through the trial. Patients may be involved in the study for about eight months, including a pre-study assessment period and safety follow-up visit.

This is a paradigm shift in the way we look at gliomas, because the ADC model has the potential to revolutionize the way we deliver chemotherapy to cancer cells while sparing the surrounding healthy tissue." adds Rixe.

"Our goal is to improve the benefits-risk ratio of treatment by increasing anti-tumor activity while reducing the side effects of toxicity on healthy tissue."

The clinical trial of AMG 595, the experimental drug being used in the study, is sponsored by Amgen, a biotechnology company based in Thousand Oaks, California.

More than 22,000 people in the United States are diagnosed with a primary malignant brain tumor every year, according to the National Cancer Institute, and the majority of these are malignant gliomas which have a poor prognosis.

In 2011, the UC Cancer Institute partnered with the UC Neuroscience Institute's Brain Tumor Center to launch a translational research program aimed at understanding the biological mechanisms of cancer's spread to the brain and developing more effective ways to treat the condition.

Both programs are part of the Cincinnati Cancer Center, a joint cancer program involving the UC College of Medicine, Cincinnati Children's Hospital Medical Center and UC Health. The collaborative initiative brings together interdisciplinary research teams of caring scientists and health professionals to research and develop new cures, while providing a continuum of care for children, adults and families with cancer.


'/>"/>
Contact: Amanda Harper
amanda.harper@uc.edu
513-558-4657
University of Cincinnati Academic Health Center
Source:Eurekalert

Related medicine news :

1. Cancer-targeting investigational nanoparticle receives FDA IND approval for first-in-human trial
2. Using Viagra to combat malignant melanoma
3. Elusive gene mutations found for malignant brain tumor
4. Agent selectively targets malignant B cells in chronic leukemia, study shows
5. Malignant brain tumors: Benefit of PET and PET/CT in the detection of recurrences is not assessable
6. Huge pelvi-abdominal malignant inflammatory myofibroblastic tumor
7. Novel RNA interference screening technique identifies possible path for malignant glioma treatment
8. CD97 gene expression and function correlate with WT1 protein expression and glioma invasiveness
9. RTOG activates study to determine best treatment strategies for patients with glioma brain tumors
10. Photons vs. protons for treatment of spinal cord gliomas
11. Discordance among commercially-available diagnostics for latent TB infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... , June 23, 2016 Research ... Pharma News Issue 52" report to their offering. ... in influenza treatment creates a favourable commercial environment for MedImmune ... growing patient base that will serve to drive considerable growth ... vaccine would serve to cap sales considerably, but development is ...
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening ... industry leaders in advanced audiology and hearing aid technology, ... ™, the world,s first internet connected hearing aid that ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... ,world firsts,: , TwinLink™ - the first ...
Breaking Medicine Technology: